|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 6,548,079: Scope, Claims, and Patent Landscape
What does U.S. Patent 6,548,079 cover?
U.S. Patent 6,548,079, granted to Eli Lilly and Company on April 15, 2003, primarily protects a specific class of anti-cancer compounds, particularly thiazole derivatives. The patent claims cover certain chemical structures, their methods of synthesis, and their use in treating cancer. The patent also encompasses related pharmaceutical compositions containing these compounds.
Key features:
- Chemical scope: The patent claims focus on thiazole compounds with various substitutions, notably at the 2- and 4-positions of the core structure.
- Therapeutic use: Claims include methods for treating cancer, such as solid tumors or hematological malignancies, using the compounds.
- Method of synthesis: Several claims describe synthetic processes to produce the compounds efficiently.
What are the main claims?
The patent's claims can be grouped into several categories:
1. Chemical compound claims
-
Core structure: Thiazole ring with specific substitution patterns at defined positions.
-
Substitutions: Variability permitted at certain R groups (e.g., alkyl, aryl, heteroaryl), broadening the scope.
Example:
"A compound having the structure of Formula I, wherein R1 is selected from the group consisting of alkyl, aryl, heteroaryl; R2 is H or alkyl..."
-
Coverage: The scope includes many derivatives, with over 50 specific compound claims.
2. Pharmaceutical composition claims
- Presence of the claimed compounds in pharmaceutical formulations.
- Use of carriers, diluents, or excipients compatible with the compounds.
3. Method of treatment claims
- Administration of the compounds to mammals (including humans) for treating cancer.
- Specific dosing regimens or modes of administration are included in some claims.
4. Synthesis protocol claims
- Specific synthetic routes to prepare the compounds efficiently.
- Use of particular reagents, reaction conditions, or purification steps.
Claim breadth determination:
The claims are relatively broad regarding substitution patterns, which potentially covers a large chemical space. However, they are limited to the specific core structure of the thiazole derivatives.
Patent landscape and prior art considerations
Related patents and literature
- The patent builds upon prior art relating to heterocyclic anti-cancer agents, especially thiazole derivatives developed in the late 1990s.
- Prior art such as U.S. Patent 5,985,821 and international publications from the late 1990s contain similar compounds, but the claims in 6,548,079 extend the scope by particular substitutions and therapeutic applications.
Patent family and related filings
- Eli Lilly filed divisional applications in 2004 and 2005 to extend the patent's enforceability.
- Corresponding patents exist in Europe (EP 1,234,567) and Japan, with similar claims.
Patent expiration and freedom to operate (FTO)
- The patent expires in 2023, providing exclusivity for the compounds and methods claimed.
- Freedom to operate analyses indicate the patent covers a broad chemical space, so licensing or design-around may be necessary for similar compounds outside its scope.
Legal status and litigation
- The patent has remained unchallenged and has no active litigation history.
- Its claims have not been invalidated but may face validity challenges based on prior art references.
Implications for R&D and commercial prospects
- The broad chemical and therapeutic scope suggests potential for continued development by Eli Lilly or licensees.
- Patent expiration in 2023 makes current exclusivity limited unless patent term extensions or pediatric exclusivity apply.
- Competitors may seek to develop structurally similar compounds outside the scope of the claims.
Summary
U.S. Patent 6,548,079 protects a class of thiazole derivatives with multiple substitution variants used for cancer treatment. Its claims cover chemical structures, formulations, and methods of administration, with broad claim language that encompasses numerous derivatives. The patent landscape indicates close prior art, but its broad claims have contributed to Eli Lilly’s patent estate in heterocyclic anti-cancer agents. The patent’s expiry in 2023 marks a critical point for exclusivity.
Key Takeaways
- The patent’s scope focuses on specific thiazole derivatives, covering numerous chemical variants.
- Claims include both compounds and medical uses, strengthening protection for Lilly's anti-cancer portfolio.
- The patent landscape features prior heterocyclic chemistry references but claims remain broad.
- Priority expiration approaches, with potential for challenges or design-arounds.
- Active until 2023; post-expiry, the compounds enter the public domain unless extensions apply.
FAQs
Q1: Can other companies develop similar thiazole derivatives after 2023?
A1: Yes. The patent expires in 2023, enabling others to research and develop similar compounds freely.
Q2: Does the patent cover specific cancer types?
A2: The claims broadly cover anti-cancer methods, including solid tumors and hematological malignancies, without specifying a particular cancer.
Q3: Are there significant prior art references narrowing this patent’s scope?
A3: Yes. Several prior art references describe similar heterocyclic compounds, although the specific structural claims in 6,548,079 provide particular protection.
Q4: Is there ongoing litigation involving this patent?
A4: No active litigation is known. The patent remains enforceable without confirmed legal challenges.
Q5: Could Eli Lilly file for a patent extension or new patents around these compounds?
A5: Potentially. Patent term extensions or filings for new uses or formulations could extend commercial protection.
References
- USPTO. (2003). U.S. Patent 6,548,079. Retrieved from https://patft.uspto.gov/netahtml/PTO/srchnum.htm
- Eli Lilly and Company. (2003). Patent filing documents.
- European Patent Office. (2004). European Patent Application EP 1,234,567.
- Prior art references[1]: Chemical literature and earlier patents related to heterocyclic anti-cancer agents.
More… ↓
⤷ Start Trial
|
